Immunoluminometric assay for measurement of the C-terminal endothelin-I precursor fragment in human plasma

Clinical Chemistry

Volumn 52, Issue 6, 2006, Pages 1144-1151

  Papassotiriou, Jana ^a   Morgenthaler, Nils G ^a   Struck, Joachim ^a   Alonso, Christine ^a   Bergmann, Andreas ^a  

^a BRAHMS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARBOXY TERMINAL ENDOTHELIN 1 PRECURSOR FRAGMENT; CITRIC ACID; EDETIC ACID; ENDOTHELIN 1; HEPARIN; PLASMA PROTEIN; POLYCLONAL ANTIBODY; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CRITICAL ILLNESS; DILUTION; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; LUMINESCENCE IMMUNOASSAY; MALE; MEASUREMENT; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SEPSIS;

CHEMILUMINESCENT MEASUREMENTS; ENDOTHELIN-1; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOASSAY; MALE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; REFERENCE VALUES; SEPSIS;

EID: 33646929754     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.065581     Document Type: Article

References (44)

1. Masaki T. Historical review: endothelin. Trends Pharmacol Sci 2004;25:219-24.
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
3. Agapitov AV, Haynes WG. Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2002;3:1-15.
4. Luscher TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002;106:2666-72.
5. Battistini B, Forget MA, Laight D. Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines. Shock 1996;5:167-83.
6. Wanecek M, Weitzberg E, Rudehill A, Oldner A. The endothelin system in septic and endotoxin shock. Eur J Pharmacol 2000;407:1-15.
7. Weitzberg E, Ahlborg G, Lundberg JM. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 1991;180:1298-303.
8. 125I-endothelin in the rat: importance of pulmonary clearance. Biochem Biophys Res Commun 1990;167:1191-5.
9. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988;85:9797-800.
10. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 1998;97:2323-30.
11. Brunner F, Stessel H, Watzinger N, Loffler BM, Opie LH. Binding of endothelin to plasma proteins and tissue receptors: effects on endothelin determination, vasoactivity, and tissue kinetics. FEBS Lett 1995;373:97-101.
12. Rossi GP, Seccia TM, Albertin G, Pessina AC. Measurement of endothelin: clinical and research use. Ann Clin Biochem 2000;37:608-26.
13. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-85.
14. Hemsen A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM. Metabolism of big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept 1995;55:287-97.
15. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol 1997;159:1987-92.
16. IS. Struck J, Morgenthaler NG, Bergmann A. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 2005;26:2482-6.
17. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823-9.
18. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9.
19. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
20. Frank EL, Hughes MP, Bankson DD, Roberts WL Effects of anticoagulants and contemporary blood collection containers on aluminum, copper, and zinc results. Clin Chem 2001;47:1109-12.
21. Ungaro B, Corso G, Dello Russo A. Cholesterol concentration in serum-plasma pairs differs because of water shift from blood cells. Clin Chem 1985;31:1096-7.
22. Suzuki N, Matsumoto H, Miyauchi T, Kitada C, Tsuda M, Goto K, et al. Sandwich-enzyme immunoassays for endothelin family peptides. J Cardiovasc Pharmacol 1991;17(Suppl 7):S420-2.
23. Rolinski B, Sadri I, Bogner J, Goebel FD. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med (Berl) 1994;194:9-24.
24. Matsumoto H, Suzuki N, Kitada C, Fujino M. Endothelin family peptides in human plasma and urine: their molecular forms and concentrations. Peptides 1994;15:505-10.
25. Aubin P, Le Brun G, Moldovan F, Villette JM, Creminon C, Dumas J, et al. Sandwich-type enzyme immunoassay for big endothelin-1 in plasmai concentrations in healthy human subjects unaffected by sex or posture. Clin Chem 1997;43:64-70.
26. Suzuki N, Matsumoto H, Kitada C, Kimura S, Miyauchi T, Fujino M. A sandwich-type enzyme immunoassay to detect immunoreactive big-endothelin-1 in plasma. J Immunol Methods 1990;127:165-70.
27. Parker JD, Thiessen JJ. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol 2004;286:H1141-5.
28. Avontuur JA, Boomsma F, van den Meiracker AH, de Jong FH, Bruining HA. Endothelin-1 and blood pressure after inhibition of nitric oxide synthesis in human septic shock. Circulation 1999;99:271-5.
29. Tschalkowsky K, Sagner S, Lehnert N, Kaul M, Ritter J. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med 2000;28:1854-60.
30. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-6.
31. Jernberg T, Stridsberg M, Lindahl B. Usefulness of plasma N-terminal proatrial natriuretic peptide (proANP) as an early predictor of outcome in unstable angina pectoris or non-ST-elevation acute myocardial infarction. Am J Cardiol 2002;89:64-6.
32. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003;24:341-56.
33. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004;341:41-8.
34. Morgenthaler NG, Struck J, Christ-Grain M, Bergmann A, Muller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005;9:R37-45.
35. Struck J, Tao C, Morgenthaler NG, Bergmann A. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004;25:1369-72.
36. Christ-Grain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005;9: R816-24.
37. Horwitz DL, Kuzuya H, Rubenstein AH. Circulating serum C-peptide: a brief review of diagnostic implications. N Engl J Med 1976;295:207-9.
38. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26:2500-4.
39. Pittet JF, Morel DR, Hemsen A, Gunning K, Lacroix JS, Suter PM, et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 1991;213:261-4.
40. Weitzberg E, Lundberg JM, Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock 1991;33:222-7.
41. Voerman HJ, Stehouwer CD, van Kamp GJ, Strack van Schijndel RJ, Groeneveld AB, Thijs LG. Plasma endothelin levels are increased during septic shock. Crit Care Med 1992;20:1097-101.
42. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-9.
43. Channick RN, Simonneau G, Sitbon O, Bobbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23.
44. Rubin LI, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.